MRI measures of neuroprotection and repair in multiple sclerosis

Journal of the Neurological Sciences

Volumn 311, Issue SUPPL. 1, 2011, Pages

  Inglese, Matilde ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

Clinical trials; Demyelination; Magnetic resonance imaging; Multiple sclerosis; Neurodegeneration

Indexed keywords

BETA INTERFERON; GADOLINIUM; GLATIRAMER;

ARTICLE; BRAIN ATROPHY; BRAIN DAMAGE; BRAIN SIZE; DIFFUSION TENSOR IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GRAY MATTER; HUMAN; MAGNETIZATION TRANSFER RATIO; MEDICAL EXPERT; MULTIPLE SCLEROSIS; NERVE REGENERATION; NETHERLANDS; NEUROIMAGING; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOLOGICAL PARAMETERS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROIMAGING; NEUROPROTECTIVE AGENTS;

EID: 84855223371     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/S0022-510X(11)70004-1     Document Type: Article

References (84)

1. F Barkhof, PA Calabresi, DH Miller, SC Reingold Imaging outcomes for neuroprotection and repair in multiple sclerosis trials Nat Rev Neurol 5 2009 256 266
2. JH van Waesberghe, W Kamphorst, CJ De Groot et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability Ann Neurol 46 1999 747 754 (Pubitemid 29518136)
3. JH van Waesberghe, MA van Walderveen, JA Castelijns et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR AJNR Am J Neuroradiol 19 1998 675 683 (Pubitemid 30422711)
4. R Zivadinov, TP Leist Clinical-magnetic resonance imaging correlations in multiple sclerosis J Neuroimaging 15 2005 10S 21S (Pubitemid 43010528)
5. F Barkhof, GB Karas, MA van Walderveen T1 hypointensities and axonal loss Neuroimaging Clin N Am 10 2000 739 752 ix. (Pubitemid 32391265)
6. L Truyen, JH van Waesberghe, MA van Walderveen et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis Neurology 47 1996 1469 1476 (Pubitemid 26422538)
7. M Filippi, M Rovaris, MA Rocca, MP Sormani, JS Wolinsky, G Comi Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes" Neurology 57 2001 731 733 (Pubitemid 32783013)
8. CM Dalton, KA Miszkiel, GJ Barker et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis J Neurol 251 2004 407 413 (Pubitemid 38501297)
9. JH Simon, J Lull, LD Jacobs et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group Neurology 55 2000 185 192 (Pubitemid 30604616)
10. C Gasperini, C Pozzilli, S Bastianello et al. Interferon-beta-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images J Neurol Neurosurg Psychiatry 67 1999 579 584 (Pubitemid 29486203)
11. C Gasperini, A Paolillo, E Giugni et al. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a Mult Scler 8 2002 119 123 (Pubitemid 34256748)
12. F Bagnato, S Gupta, ND Richert et al. Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations Arch Neurol 62 2005 1684 1688 (Pubitemid 41626663)
13. DD Mikol, F Barkhof, P Chang et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial Lancet Neurol 2008
14. D Cadavid, J Cheriyan, J Skurnick, JA Lincoln, LJ Wolansky, SD Cook New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate J Neurol Neurosurg Psychiatry 80 2009 1337 1343
15. P O'Connor, M Filippi, B Arnason et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study Lancet Neurol 8 2009 889 897
16. IJ van den Elskamp, J Lembcke, V Dattola et al. Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis Mult Scler 14 2008 764 769
17. SM Smith, N De Stefano, M Jenkinson, PM Matthews Normalized accurate measurement of longitudinal brain change J Comput Assist Tomogr 25 2001 466 475 (Pubitemid 32440803)
18. RA Rudick, E Fisher, JC Lee, J Simon, L Jacobs Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group Neurology 53 1999 1698 1704 (Pubitemid 29530342)
19. MP Amato, E Portaccio, B Goretti et al. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis Arch Neurol 64 2007 1157 1161 (Pubitemid 47258075)
20. E Fisher, JC Lee, K Nakamura, RA Rudick Gray matter atrophy in multiple sclerosis: a longitudinal study Ann Neurol 64 2008 255 265
21. CM Dalton, DT Chard, GR Davies et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes Brain 127 2004 1101 1107 (Pubitemid 38623045)
22. De Stefano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology;74:1868-76.
23. SS Jordy, CP Tilbery, MM Fazzito Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases Arq Neuropsiquiatr 66 2008 11 14 (Pubitemid 351520709)
24. N De Stefano, PM Matthews, M Filippi et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability Neurology 60 2003 1157 1162 (Pubitemid 36418778)
25. SA Gauthier, AM Berger, Z Liptak et al. Rate of brain atrophy in benign vs. early multiple sclerosis Arch Neurol 66 2009 234 237
26. JH Simon, LD Jacobs, MK Campion et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Neurology 53 1999 139 148 (Pubitemid 29329662)
27. R Zivadinov, M Stosic, JL Cox, DP Ramasamy, MG Dwyer The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome J Neurol 255 Suppl 1 2008 61 74 (Pubitemid 351341874)
28. IJ van den Elskamp, B Boden, V Dattola et al. Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis Neuroradiology 52 10 2010 875 881
29. LK Fisniku, DT Chard, JS Jackson et al. Gray matter atrophy is related to long-term disability in multiple sclerosis Ann Neurol 64 2008 247 254
30. DT Chard, CM Griffin, W Rashid et al. Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis Mult Scler 10 2004 387 391 (Pubitemid 39117333)
31. M Tiberio, DT Chard, DR Altmann et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study Neurology 64 2005 1001 1007 (Pubitemid 40388451)
32. E Pagani, MA Rocca, A Gallo et al. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype AJNR Am J Neuroradiol 26 2005 341 346 (Pubitemid 43073310)
33. A Tekok-Kilic, RH Benedict, B Weinstock-Guttman et al. Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis Neuroimage 36 2007 1294 1300 (Pubitemid 47007715)
34. M Calabrese, F Agosta, F Rinaldi et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis Arch Neurol 66 2009 1144 1150
35. J Sepulcre, JC Masdeu, J Goni et al. Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways Mult Scler 15 2009 337 344
36. R Zivadinov, L Locatelli, D Cookfair et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy Mult Scler 13 2007 490 501 (Pubitemid 46796509)
37. K Bendfeldt, H Egger, TE Nichols et al. Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis - a longitudinal MRI study Brain Res 1325 2010 174 182
38. GB Pike Magnetization transfer imaging of multiple sclerosis Ital J Neurol Sci 18 1997 359 365 (Pubitemid 128730980)
39. A Traboulsee, J Dehmeshki, KR Peters et al. Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities Mult Scler 9 2003 566 573 (Pubitemid 37479404)
40. K Schmierer, F Scaravilli, DR Altmann, GJ Barker, DH Miller Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain Ann Neurol 56 2004 407 415 (Pubitemid 39166560)
41. F Barkhof, W Bruck, CJ De Groot et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance Arch Neurol 60 2003 1073 1081 (Pubitemid 36975794)
42. N Richert, F Bagnato, T Howard et al. Whole brain magnetization transfer analysis of relapsing-remitting multiple sclerosis patients treated with IFNB-1b or glatiramer acetate Multiple Sclerosis 9 2003 S64
43. O Khan, M Mackenzie, Y Shen, I Zak, Z Latif, C Caon Combined brain MTR and H-MRS multi-modality approach to investigate mechanism of action of interferon beta and glatiramer acetate in RRMS Neurology 68 Suppl 2007 P02.058
44. ND Richert, JL Ostuni, CN Bash, TP Leist, HF McFarland, JA Frank Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis Mult Scler 7 2001 49 58 (Pubitemid 32396579)
45. M Kita, DE Goodkin, P Bacchetti, E Waubant, SJ Nelson, S Majumdar Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a Neurology 54 2000 1741 1745 (Pubitemid 30428399)
46. ND Richert, JL Ostuni, CN Bash, JH Duyn, HF McFarland, JA Frank Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b AJNR Am J Neuroradiol 19 1998 1705 1713 (Pubitemid 30413762)
47. M Inglese, JH van Waesberghe, M Rovaris et al. The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS Neurology 60 2003 853 860 (Pubitemid 36297373)
48. van den Elskamp IJ, Knol DL, Vrenken H, et al. Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis. Mult Scler;16:660-9.
49. JT Chen, DL Collins, HL Atkins, MS Freedman, DL Arnold Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions Ann Neurol 63 2008 254 262 (Pubitemid 351355304)
50. ML Simmons, CG Frondoza, JT Coyle Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies Neuroscience 45 1991 37 45
51. JR Moffett, B Ross, P Arun, CN Madhavarao, AM Namboodiri N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology Prog Neurobiol 81 2007 89 131 (Pubitemid 46282272)
52. C Bjartmar, G Kidd, S Mork, R Rudick, BD Trapp Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients Ann Neurol 48 2000 893 901
53. R Dutta, J McDonough, X Yin et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients Ann Neurol 59 2006 478 489 (Pubitemid 43358068)
54. DL Arnold, PM Matthews, G Francis, J Antel Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease Magn Reson Med 14 1990 154 159 (Pubitemid 20243873)
55. N De Stefano, PM Matthews, JP Antel, M Preul, G Francis, DL Arnold Chemical pathology of acute demyelinating lesions and its correlation with disability Ann Neurol 38 1995 901 909 (Pubitemid 26004072)
56. CA Davie, GJ Barker, AJ Thompson, PS Tofts, WI McDonald, DH Miller 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis J Neurol Neurosurg Psychiatry 63 1997 736 742 (Pubitemid 27520749)
57. R Sharma, PA Narayana, JS Wolinsky Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging Mult Scler 7 2001 221 226 (Pubitemid 32780691)
58. M Inglese, S Liu, JS Babb, LJ Mannon, RI Grossman, O Gonen Three-dimensional proton spectroscopy of deep gray matter nuclei in relapsing-remitting MS Neurology 63 2004 170 172 (Pubitemid 38943801)
59. DL Arnold Magnetic resonance spectroscopy: imaging axonal damage in MS J Neuroimmunol 98 1999 2 6 (Pubitemid 29295400)
60. N De Stefano, PM Matthews, L Fu et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study Brain 121 Pt 8 1998 1469 1477 (Pubitemid 28349900)
61. O Khan, Y Shen, F Bao et al. Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-term H-MRS monitoring in multiple sclerosis J Neuroimaging 18 2008 314 319
62. S Narayanan, Z Caramanos, D Arnold The effect of glatiramer acetate treatment on axonal integrity in multiple sclerosis Mult Scler 10 2004 S256
63. P Sarchielli, O Presciutti, R Tarducci et al. 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study J Neurol Neurosurg Psychiatry 64 1998 204 212 (Pubitemid 28159802)
64. S Narayanan, N De Stefano, GS Francis et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b J Neurol 248 2001 979 986 (Pubitemid 36124725)
65. A Parry, R Corkill, AM Blamire et al. Beta-interferon treatment does not always slow the progression of axonal injury in multiple sclerosis J Neurol 250 2003 171 178 (Pubitemid 36223091)
66. B Cree, H Ratiney, M Owen, A Evangelista, J Oh, D Pelletier Magnetic resonance spectroscopy effects of natalizumab: single center results from the SENTINEL study Neurology 2007
67. N De Stefano, M Filippi, D Miller et al. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies Neurology 69 2007 1942 1952 (Pubitemid 350100353)
68. G Comi, V Martinelli, M Rodegher et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial Lancet 374 2009 1503 1511
69. D Arnold, S Narayanan, S Antel Treatment with glatiramer acetate protects axons in patients with clinically isolated syndromes: evidence from the PreCISe trial Multiple Sclerosis 14 2008 S10
70. V Parisi, G Manni, M Spadaro et al. Correlation between morphological and functional retinal impairment in multiple sclerosis patients Invest Ophthalmol Vis Sci 40 1999 2520 2527 (Pubitemid 29455479)
71. JB Fisher, DA Jacobs, CE Markowitz et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis Ophthalmology 113 2006 324 332 (Pubitemid 43170783)
72. SA Trip, PG Schlottmann, SJ Jones et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis Ann Neurol 58 2005 383 391 (Pubitemid 41266624)
73. SA Trip, C Wheeler-Kingshott, SJ Jones et al. Optic nerve diffusion tensor imaging in optic neuritis Neuroimage 30 2006 498 505
74. E Gordon-Lipkin, B Chodkowski, DS Reich et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis Neurology 69 2007 1603 1609 (Pubitemid 350287144)
75. EM Frohman, MG Dwyer, T Frohman et al. Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: a pilot study J Neurol Sci 282 2009 96 105
76. Henderson AP, Trip SA, Schlottmann PG, et al. A preliminary longitudinal study of the retinal nerve fiber layer in progressive multiple sclerosis. J Neurol;257:1083-91.
77. Talman LS, Bisker ER, Sackel DJ, et al. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol;67:749-60.
78. Calabrese M, Rocca MA, Atzori M, et al. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. Ann Neurol;67:376-83.
79. K Kollia, S Maderwald, N Putzki et al. First clinical study on ultra-high-field MR imaging in patients with multiple sclerosis: comparison of 1.5T and 7T AJNR Am J Neuroradiol 30 2009 699 702
80. R Srinivasan, N Sailasuta, R Hurd, S Nelson, D Pelletier Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T Brain 128 2005 1016 1025 (Pubitemid 40675457)
81. R Srinivasan, H Ratiney, KE Hammond-Rosenbluth, D Pelletier, SJ Nelson MR spectroscopic imaging of glutathione in the white and gray matter at 7 T with an application to multiple sclerosis Magn Reson Imaging 28 2010 163 170
82. M Inglese, G Madelin, N Oesingmann et al. Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla Brain 133 2010 847 857
83. MM Vellinga, H Vrenken, HE Hulst et al. Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: an exploratory study J Magn Reson Imaging 29 2009 774 779
84. B Stankoff, Y Wang, M Bottlaender et al. Imaging of CNS myelin by positronemission tomography Proc Natl Acad Sci U S A 103 2006 9304 9309 (Pubitemid 43902573)